Development of live attenuated Streptococcus agalactiae vaccine for tilapia via continuous passage in vitro
Fish Streptococcus agalactiae (S. agalactiae) seriously harms the world's aquaculture industry and causes huge economic losses. This study aimed to develop a potential live attenuated vaccine of S. agalactiae. Pre-screened vaccine candidate strain S. agalactiae HN016 was used as starting materi...
Gespeichert in:
| Veröffentlicht in: | Fish & shellfish immunology 2015-08, Vol.45 (2), p.955-963 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 963 |
|---|---|
| container_issue | 2 |
| container_start_page | 955 |
| container_title | Fish & shellfish immunology |
| container_volume | 45 |
| creator | Li, L.P. Wang, R. Liang, W.W. Huang, T. Huang, Y. Luo, F.G. Lei, A.Y. Chen, M. Gan, X. |
| description | Fish Streptococcus agalactiae (S. agalactiae) seriously harms the world's aquaculture industry and causes huge economic losses. This study aimed to develop a potential live attenuated vaccine of S. agalactiae. Pre-screened vaccine candidate strain S. agalactiae HN016 was used as starting material to generate an attenuated strain S. agalactiae YM001 by continuous passage in vitro. The biological characteristics, virulence, and stability of YM001 were detected, and the protective efficacy of YM001 immunization in tilapia was also determined. Our results indicated that the growth, staining, characteristics of pulsed-field gel electrophoresis (PFGE) genotype, and virulence of YM001 were changed significantly as compared to the parental strain HN016. High doses of YM001 by intraperitoneal (IP) injection (1.0 × 109 CFU/fish) and oral gavage (1.0 × 1010 CFU/fish) respectively did not cause any mortality and morbidity in tilapia. The relative percent survivals (RPSs) of fishes immunized with YM001 (1.0 × 108 CFU/fish, one time) via injection, immersion, and oral administration were 96.88, 67.22, and 71.81%, respectively, at 15 days, and 93.61, 60.56, and 53.16%, respectively, at 30 days. In all tests with 1–3 times of immunization in tilapia, the dosages at 1 × 108 and 1 × 109 CFU/fish displayed the similar best results, whereas the immunoprotection of the dosages at 1 × 106 and 1 × 107 CFU/fish declined significantly (P |
| doi_str_mv | 10.1016/j.fsi.2015.06.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1735921820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1050464815300425</els_id><sourcerecordid>1735921820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c316t-189419a299956aaa053b5b712906b0c779a26e789499cef143a186a2dca52dfb3</originalsourceid><addsrcrecordid>eNqFkc-K1TAUh4Mozjj6AG4kSzetJ2mTNriS8c8MDLhQ1-E0PR1y6W1qkhZ8G5_FJzOXO7rURUgg3-_H4XyMvRRQCxD6zaGekq8lCFWDrkG0j9ilAKMqY9ru8emtoGp121-wZykdAEA3Gp6yC6mh72SnL9n8nnaaw3qkJfMw8dnvxDFnWjbMNPIvOdKagwvObYnjPc7oskfiOzrnF-JTiDz7GVePfC_HhSX7ZQuFXjElvCful18_d59jeM6eTDgnevFwX7FvHz98vb6p7j5_ur1-d1e5Ruhcid60wqA0xiiNiKCaQQ2dkAb0AK7ryp-mrlDGOJpE26DoNcrRoZLjNDRX7PW5d43h-0Yp26NPjuYZFyqDWdE1ykjRS_g_qo3qlJaNLKg4oy6GlCJNdo3-iPGHFWBPPuzBFh_25MOCtsVHybx6qN-GI41_E38EFODtGaCyj91TtMl5WhyNPpLLdgz-H_W_AViRnOc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695756232</pqid></control><display><type>article</type><title>Development of live attenuated Streptococcus agalactiae vaccine for tilapia via continuous passage in vitro</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Li, L.P. ; Wang, R. ; Liang, W.W. ; Huang, T. ; Huang, Y. ; Luo, F.G. ; Lei, A.Y. ; Chen, M. ; Gan, X.</creator><creatorcontrib>Li, L.P. ; Wang, R. ; Liang, W.W. ; Huang, T. ; Huang, Y. ; Luo, F.G. ; Lei, A.Y. ; Chen, M. ; Gan, X.</creatorcontrib><description>Fish Streptococcus agalactiae (S. agalactiae) seriously harms the world's aquaculture industry and causes huge economic losses. This study aimed to develop a potential live attenuated vaccine of S. agalactiae. Pre-screened vaccine candidate strain S. agalactiae HN016 was used as starting material to generate an attenuated strain S. agalactiae YM001 by continuous passage in vitro. The biological characteristics, virulence, and stability of YM001 were detected, and the protective efficacy of YM001 immunization in tilapia was also determined. Our results indicated that the growth, staining, characteristics of pulsed-field gel electrophoresis (PFGE) genotype, and virulence of YM001 were changed significantly as compared to the parental strain HN016. High doses of YM001 by intraperitoneal (IP) injection (1.0 × 109 CFU/fish) and oral gavage (1.0 × 1010 CFU/fish) respectively did not cause any mortality and morbidity in tilapia. The relative percent survivals (RPSs) of fishes immunized with YM001 (1.0 × 108 CFU/fish, one time) via injection, immersion, and oral administration were 96.88, 67.22, and 71.81%, respectively, at 15 days, and 93.61, 60.56, and 53.16%, respectively, at 30 days. In all tests with 1–3 times of immunization in tilapia, the dosages at 1 × 108 and 1 × 109 CFU/fish displayed the similar best results, whereas the immunoprotection of the dosages at 1 × 106 and 1 × 107 CFU/fish declined significantly (P < 0.01), and 1 × 105 CFU/fish hardly displayed any protective effect. In addition, the efficacy of 2–3 times of immunization was significantly higher than that of single immunization (P < 0.01) while no significant difference in the efficacy between twice and thrice of immunization was seen (P > 0.05). The level of protective antibody elicited by oral immunization was significantly higher compared to that of the control group (P < 0.01), and the antibody reached their maximum levels 14–21 days after the immunization but decreased significantly after 28 days of vaccination. YM001 bacteria were isolated from the brain, liver, kidney, and spleen tissues of fish after oral immunization and the bacteria existed for the longest time in the spleen (up to 15 days). Taken together, this study obtained a safe, stable, and highly immunogenic attenuated S. agalactiae strain YM001; oral immunization of tilapia with this strain produced a good immune protection.
•Streptococcus agalactiae seriously harms the world's aquaculture industry.•Obtained a safe, stable, and highly immunogenic attenuated S. agalactiae strain YM001.•Oral immunization of tilapia with YM001 produced a good immune protection.</description><identifier>ISSN: 1050-4648</identifier><identifier>EISSN: 1095-9947</identifier><identifier>DOI: 10.1016/j.fsi.2015.06.014</identifier><identifier>PMID: 26087276</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Administration, Oral ; Animals ; Attenuated vaccine ; Bacterial Vaccines - immunology ; Cichlids ; Fish Diseases - immunology ; Fish Diseases - microbiology ; Oral immunization ; Streptococcal Infections - immunology ; Streptococcal Infections - microbiology ; Streptococcal Infections - veterinary ; Streptococcus agalactiae ; Streptococcus agalactiae - physiology ; Tilapia ; Vaccines, Attenuated - immunology ; Virulence</subject><ispartof>Fish & shellfish immunology, 2015-08, Vol.45 (2), p.955-963</ispartof><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c316t-189419a299956aaa053b5b712906b0c779a26e789499cef143a186a2dca52dfb3</citedby><cites>FETCH-LOGICAL-c316t-189419a299956aaa053b5b712906b0c779a26e789499cef143a186a2dca52dfb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.fsi.2015.06.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26087276$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, L.P.</creatorcontrib><creatorcontrib>Wang, R.</creatorcontrib><creatorcontrib>Liang, W.W.</creatorcontrib><creatorcontrib>Huang, T.</creatorcontrib><creatorcontrib>Huang, Y.</creatorcontrib><creatorcontrib>Luo, F.G.</creatorcontrib><creatorcontrib>Lei, A.Y.</creatorcontrib><creatorcontrib>Chen, M.</creatorcontrib><creatorcontrib>Gan, X.</creatorcontrib><title>Development of live attenuated Streptococcus agalactiae vaccine for tilapia via continuous passage in vitro</title><title>Fish & shellfish immunology</title><addtitle>Fish Shellfish Immunol</addtitle><description>Fish Streptococcus agalactiae (S. agalactiae) seriously harms the world's aquaculture industry and causes huge economic losses. This study aimed to develop a potential live attenuated vaccine of S. agalactiae. Pre-screened vaccine candidate strain S. agalactiae HN016 was used as starting material to generate an attenuated strain S. agalactiae YM001 by continuous passage in vitro. The biological characteristics, virulence, and stability of YM001 were detected, and the protective efficacy of YM001 immunization in tilapia was also determined. Our results indicated that the growth, staining, characteristics of pulsed-field gel electrophoresis (PFGE) genotype, and virulence of YM001 were changed significantly as compared to the parental strain HN016. High doses of YM001 by intraperitoneal (IP) injection (1.0 × 109 CFU/fish) and oral gavage (1.0 × 1010 CFU/fish) respectively did not cause any mortality and morbidity in tilapia. The relative percent survivals (RPSs) of fishes immunized with YM001 (1.0 × 108 CFU/fish, one time) via injection, immersion, and oral administration were 96.88, 67.22, and 71.81%, respectively, at 15 days, and 93.61, 60.56, and 53.16%, respectively, at 30 days. In all tests with 1–3 times of immunization in tilapia, the dosages at 1 × 108 and 1 × 109 CFU/fish displayed the similar best results, whereas the immunoprotection of the dosages at 1 × 106 and 1 × 107 CFU/fish declined significantly (P < 0.01), and 1 × 105 CFU/fish hardly displayed any protective effect. In addition, the efficacy of 2–3 times of immunization was significantly higher than that of single immunization (P < 0.01) while no significant difference in the efficacy between twice and thrice of immunization was seen (P > 0.05). The level of protective antibody elicited by oral immunization was significantly higher compared to that of the control group (P < 0.01), and the antibody reached their maximum levels 14–21 days after the immunization but decreased significantly after 28 days of vaccination. YM001 bacteria were isolated from the brain, liver, kidney, and spleen tissues of fish after oral immunization and the bacteria existed for the longest time in the spleen (up to 15 days). Taken together, this study obtained a safe, stable, and highly immunogenic attenuated S. agalactiae strain YM001; oral immunization of tilapia with this strain produced a good immune protection.
•Streptococcus agalactiae seriously harms the world's aquaculture industry.•Obtained a safe, stable, and highly immunogenic attenuated S. agalactiae strain YM001.•Oral immunization of tilapia with YM001 produced a good immune protection.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Attenuated vaccine</subject><subject>Bacterial Vaccines - immunology</subject><subject>Cichlids</subject><subject>Fish Diseases - immunology</subject><subject>Fish Diseases - microbiology</subject><subject>Oral immunization</subject><subject>Streptococcal Infections - immunology</subject><subject>Streptococcal Infections - microbiology</subject><subject>Streptococcal Infections - veterinary</subject><subject>Streptococcus agalactiae</subject><subject>Streptococcus agalactiae - physiology</subject><subject>Tilapia</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Virulence</subject><issn>1050-4648</issn><issn>1095-9947</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-K1TAUh4Mozjj6AG4kSzetJ2mTNriS8c8MDLhQ1-E0PR1y6W1qkhZ8G5_FJzOXO7rURUgg3-_H4XyMvRRQCxD6zaGekq8lCFWDrkG0j9ilAKMqY9ru8emtoGp121-wZykdAEA3Gp6yC6mh72SnL9n8nnaaw3qkJfMw8dnvxDFnWjbMNPIvOdKagwvObYnjPc7oskfiOzrnF-JTiDz7GVePfC_HhSX7ZQuFXjElvCful18_d59jeM6eTDgnevFwX7FvHz98vb6p7j5_ur1-d1e5Ruhcid60wqA0xiiNiKCaQQ2dkAb0AK7ryp-mrlDGOJpE26DoNcrRoZLjNDRX7PW5d43h-0Yp26NPjuYZFyqDWdE1ykjRS_g_qo3qlJaNLKg4oy6GlCJNdo3-iPGHFWBPPuzBFh_25MOCtsVHybx6qN-GI41_E38EFODtGaCyj91TtMl5WhyNPpLLdgz-H_W_AViRnOc</recordid><startdate>201508</startdate><enddate>201508</enddate><creator>Li, L.P.</creator><creator>Wang, R.</creator><creator>Liang, W.W.</creator><creator>Huang, T.</creator><creator>Huang, Y.</creator><creator>Luo, F.G.</creator><creator>Lei, A.Y.</creator><creator>Chen, M.</creator><creator>Gan, X.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>F1W</scope><scope>H94</scope><scope>H95</scope><scope>H98</scope><scope>L.G</scope></search><sort><creationdate>201508</creationdate><title>Development of live attenuated Streptococcus agalactiae vaccine for tilapia via continuous passage in vitro</title><author>Li, L.P. ; Wang, R. ; Liang, W.W. ; Huang, T. ; Huang, Y. ; Luo, F.G. ; Lei, A.Y. ; Chen, M. ; Gan, X.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c316t-189419a299956aaa053b5b712906b0c779a26e789499cef143a186a2dca52dfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Attenuated vaccine</topic><topic>Bacterial Vaccines - immunology</topic><topic>Cichlids</topic><topic>Fish Diseases - immunology</topic><topic>Fish Diseases - microbiology</topic><topic>Oral immunization</topic><topic>Streptococcal Infections - immunology</topic><topic>Streptococcal Infections - microbiology</topic><topic>Streptococcal Infections - veterinary</topic><topic>Streptococcus agalactiae</topic><topic>Streptococcus agalactiae - physiology</topic><topic>Tilapia</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Virulence</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, L.P.</creatorcontrib><creatorcontrib>Wang, R.</creatorcontrib><creatorcontrib>Liang, W.W.</creatorcontrib><creatorcontrib>Huang, T.</creatorcontrib><creatorcontrib>Huang, Y.</creatorcontrib><creatorcontrib>Luo, F.G.</creatorcontrib><creatorcontrib>Lei, A.Y.</creatorcontrib><creatorcontrib>Chen, M.</creatorcontrib><creatorcontrib>Gan, X.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Aquaculture Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><jtitle>Fish & shellfish immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, L.P.</au><au>Wang, R.</au><au>Liang, W.W.</au><au>Huang, T.</au><au>Huang, Y.</au><au>Luo, F.G.</au><au>Lei, A.Y.</au><au>Chen, M.</au><au>Gan, X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of live attenuated Streptococcus agalactiae vaccine for tilapia via continuous passage in vitro</atitle><jtitle>Fish & shellfish immunology</jtitle><addtitle>Fish Shellfish Immunol</addtitle><date>2015-08</date><risdate>2015</risdate><volume>45</volume><issue>2</issue><spage>955</spage><epage>963</epage><pages>955-963</pages><issn>1050-4648</issn><eissn>1095-9947</eissn><abstract>Fish Streptococcus agalactiae (S. agalactiae) seriously harms the world's aquaculture industry and causes huge economic losses. This study aimed to develop a potential live attenuated vaccine of S. agalactiae. Pre-screened vaccine candidate strain S. agalactiae HN016 was used as starting material to generate an attenuated strain S. agalactiae YM001 by continuous passage in vitro. The biological characteristics, virulence, and stability of YM001 were detected, and the protective efficacy of YM001 immunization in tilapia was also determined. Our results indicated that the growth, staining, characteristics of pulsed-field gel electrophoresis (PFGE) genotype, and virulence of YM001 were changed significantly as compared to the parental strain HN016. High doses of YM001 by intraperitoneal (IP) injection (1.0 × 109 CFU/fish) and oral gavage (1.0 × 1010 CFU/fish) respectively did not cause any mortality and morbidity in tilapia. The relative percent survivals (RPSs) of fishes immunized with YM001 (1.0 × 108 CFU/fish, one time) via injection, immersion, and oral administration were 96.88, 67.22, and 71.81%, respectively, at 15 days, and 93.61, 60.56, and 53.16%, respectively, at 30 days. In all tests with 1–3 times of immunization in tilapia, the dosages at 1 × 108 and 1 × 109 CFU/fish displayed the similar best results, whereas the immunoprotection of the dosages at 1 × 106 and 1 × 107 CFU/fish declined significantly (P < 0.01), and 1 × 105 CFU/fish hardly displayed any protective effect. In addition, the efficacy of 2–3 times of immunization was significantly higher than that of single immunization (P < 0.01) while no significant difference in the efficacy between twice and thrice of immunization was seen (P > 0.05). The level of protective antibody elicited by oral immunization was significantly higher compared to that of the control group (P < 0.01), and the antibody reached their maximum levels 14–21 days after the immunization but decreased significantly after 28 days of vaccination. YM001 bacteria were isolated from the brain, liver, kidney, and spleen tissues of fish after oral immunization and the bacteria existed for the longest time in the spleen (up to 15 days). Taken together, this study obtained a safe, stable, and highly immunogenic attenuated S. agalactiae strain YM001; oral immunization of tilapia with this strain produced a good immune protection.
•Streptococcus agalactiae seriously harms the world's aquaculture industry.•Obtained a safe, stable, and highly immunogenic attenuated S. agalactiae strain YM001.•Oral immunization of tilapia with YM001 produced a good immune protection.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26087276</pmid><doi>10.1016/j.fsi.2015.06.014</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-4648 |
| ispartof | Fish & shellfish immunology, 2015-08, Vol.45 (2), p.955-963 |
| issn | 1050-4648 1095-9947 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1735921820 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Administration, Oral Animals Attenuated vaccine Bacterial Vaccines - immunology Cichlids Fish Diseases - immunology Fish Diseases - microbiology Oral immunization Streptococcal Infections - immunology Streptococcal Infections - microbiology Streptococcal Infections - veterinary Streptococcus agalactiae Streptococcus agalactiae - physiology Tilapia Vaccines, Attenuated - immunology Virulence |
| title | Development of live attenuated Streptococcus agalactiae vaccine for tilapia via continuous passage in vitro |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A24%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20live%20attenuated%20Streptococcus%20agalactiae%20vaccine%20for%20tilapia%20via%20continuous%20passage%20in%C2%A0vitro&rft.jtitle=Fish%20&%20shellfish%20immunology&rft.au=Li,%20L.P.&rft.date=2015-08&rft.volume=45&rft.issue=2&rft.spage=955&rft.epage=963&rft.pages=955-963&rft.issn=1050-4648&rft.eissn=1095-9947&rft_id=info:doi/10.1016/j.fsi.2015.06.014&rft_dat=%3Cproquest_cross%3E1735921820%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695756232&rft_id=info:pmid/26087276&rft_els_id=S1050464815300425&rfr_iscdi=true |